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TAS2R38 is a novel modifier gene in 
patients with cystic fibrosis
Alice castaldo1,2,7, Gustavo cernera3,4,7, Paola iacotucci5,7, Chiara cimbalo1, Monica Gelzo3,4, 
Marika comegna3,4, Antonella Miriam Di Lullo6, Antonella tosco1, Vincenzo carnovale5, 
Valeria Raia1 & felice Amato  3,4*
The clinical manifestation of cystic fibrosis (CF) is heterogeneous also in patients with the same cystic 
fibrosis transmembrane regulator (CFTR) genotype and in affected sibling pairs. Other genes, inherited 
independently of CFTR, may modulate the clinical manifestation and complications of patients with 
CF, including the severity of chronic sinonasal disease and the occurrence of chronic Pseudomonas 
aeruginosa colonization. The T2R38 gene encodes a taste receptor and recently its functionality was 
related to the occurrence of sinonasal diseases and upper respiratory infections. We assessed the T2R38 
genotype in 210 patients with CF and in 95 controls, relating the genotype to the severity of sinonasal 
disease and to the occurrence of P. aeruginosa pulmonary colonization. The frequency of the PAV allele 
i.e., the allele associated with the high functionality of the T2R38 protein, was significantly lower in i) CF 
patients with nasal polyposis requiring surgery, especially in patients who developed the complication 
before 14 years of age; and ii) in CF patients with chronic pulmonary colonization by P. aeruginosa, 
especially in patients who were colonized before 14 years of age, than in control subjects. These data 
suggest a role for T2R38 as a novel modifier gene of sinonasal disease severity and of pulmonary P. 
aeruginosa colonization in patients with CF.
Cystic fibrosis is a severe autosomal recessive disease due to mutations in the cystic fibrosis transmembrane reg-
ulator (CFTR) gene. The clinical manifestation of cystic fibrosis (CF) is highly heterogeneous also depending on 
the functional effect of the CFTR genotype1,2. However, patients with the same CFTR genotype may display a 
clinical discordance3 and a percentage of sibling pairs affected by CF display a discordant clinical manifestation3,4 
reinforcing the concept that complex alleles (i.e., additional mutations on the same allele5), non-coding regions of 
CFTR6,7 or other genes, inherited independently of CFTR, modulate the clinical manifestation and complications 
of patients with CF8. Patients with CF frequently show different degrees of chronic rhinosinusitis9,10 with poor 
perception of sinonasal symptoms11 and pulmonary colonization by Pseudomonas aeruginosa and other oppor-
tunistic bacteria12,13. Chronic rhinosinusitis is common in patients affected by CF and it causes smell alterations14 
that may impair taste and cause alterations in nutrition, thus, potentially impacting overall therapy outcome15. A 
percentage of patients develop nasal turbinate hypertrophy (NTH) or nasal polyposis (NP)10. However, according 
to the US CFF registry16, only 2–3% of patients every year require surgery for NP, which is considered the final, 
most advanced step of sinonasal disease. It is still unclear why only a small subgroup of patients with CF progress 
to such phase of the sinonasal disease17–20, even though the severity of CFTR mutations as well as previous sinus 
surgery may predict an increased risk11. Interestingly, in a recent study on 101 CF sibling-pairs4 we found NP 
requiring surgery in both the siblings of 13 pairs and in only one sibling from 12 sibling pairs. The poor correla-
tion of NP to the CFTR genotype and to other clinical manifestations such as the pancreatic status and the severity 
of lung disease suggest that modifier genes play a role in determining nasal polyposis21.
P. aeruginosa is an opportunistic pathogen that frequently infects the lungs of patients with CF contributing 
to the decline in pulmonary function. P. aeruginosa expresses a series of specific virulence factors and, through 
adaptive mutations and antimicrobial resistance, causes chronic colonization via the development of biofilms22. 
In our study on CF sibling pairs4, we found chronic colonization by P. aeruginosa in 92/208 (44.2%) patients with 
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CF and 21/101 cases in which only one sibling was colonized; 11/21 of these patients lived in the same environ-
ment suggesting that the environment has a limited role in P. aeruginosa colonization. Modifier genes, inherited 
independently by CFTR, may predispose to colonization of P. aeruginosa23.
Bitter receptors are G protein-coupled proteins that detect bitter compounds ingested with the diet24. The 
T2R38 gene, originally identified in type II taste receptor cells of the tongue, encodes one of these proteins, which 
exerts a main role as bitter taste receptors with the aim of protecting the individual against the ingestion of toxic 
substances present in spoiled foods. Among these substances, the receptor recognizes bacterial products such as 
acyl-homoserine lactones secreted by several gram-negative bacteria including P. aeruginosa, and it is now known 
that T2R38 and other bitter and sweet taste receptors are widely expressed by the upper respiratory tract ciliated 
cells and by solitary nose chemosensory cells25,26. These receptors, once activated by bacterial products, modu-
late ciliary beat frequency, promote the production of NO, and stimulate the release of immune peptides27. Such 
responses are strongly reduced in subjects who carry the nonfunctional “AVI” allele, while they are more effective 
in subjects carrying the “PAV” allele25,27 of the T2R38 gene. Furthermore, this polymorphism produces changes in 
the amino acid residues at positions 49, 262, and 296, generating two common alleles: the functional taster allele 
encodes proline, alanine, and valine (PAV); and the nonfunctional non-taster allele encodes alanine, valine, and 
isoleucine (AVI). These two common alleles generate three common genotypes (i.e., PAV/PAV, PAV/AVI, and 
AVI/AVI). Various studies have described the increased occurrence of sinonasal diseases and upper respiratory 
infections in patients with altered T2R38 activity, including in patients with CF28–32.
Results
Correlation between TAS2R38 and sinonasal complications. As shown in Table 1, we evaluated the 
frequency of the PAV allele and, as shown in Fig. 1a, we evaluated the frequency of the PAV homozygous geno-
type of the TAS2R38 gene in various subgroups of CF patients with different levels of sinonasal complications, in 
comparison with those of control subjects. The PAV allele was found in 33/98 (33.7%) alleles from CF patients 
with NP requiring surgery and these figures were significantly lower than those for control subjects (p < 0.01). 
This frequency was even lower in CF patients who developed NP requiring surgery before 14 years of age (18/68 
alleles, 26.4%) and again significantly lower than that in control subjects (p < 0.01). However, the allele frequency 
of PAV was not significantly different between CF patients with NTH and control subjects. The same was true for 
CF patients with no NP or NTH.
These results were partially mirrored by the comparison of the frequency of the PAV homozygous genotype 
(Fig. 1a). It was significantly less frequent in patients with NP requiring surgery (5/49, 10.2%) than in control 
subjects (29/95, 30.5%; p < 0.01) and even lower in CF patients who developed NP requiring surgery before 14 
years of age (3/34, 8.8%); the difference with control subjects was significant (p < 0.01). Again, the frequency of 
the PAV homozygous genotype did not differ between either CF patients with NTH and patients with no NP or 
NTH compared to that for control subjects.
Correlation between TAS2R38 and P. aeruginosa chronic colonization. Table 1 shows that the fre-
quency of the PAV allele of the TAS2R38 gene was significantly lower in CF patients with P. aeruginosa chronic 
colonization (CC) (53/138, 38.4%) than in control subjects (p < 0.01), and it was even lower in patients colonized 
before 14 years of age (28/90, 31.1%), which was significantly lower (p < 0.01) than in control subjects. However, 
the frequency of the PAV allele did not differ between CF patients with no P. aeruginosa CC and control subjects. 
Again, the comparison of the frequency of the homozygous PAV allele (Fig. 1b) mirrored the results, being lower 
(though not significantly) in patients with P. aeruginosa CC (12/69 patients, 17.4%) than in control subjects, and 
even lower in CF patients colonized before 14 years of age (5/45, 11.1%), which was significantly lower than in 
control subjects (p < 0.01). No significant difference was observed between CF patients with no CC and control 
subjects.
TAS2R38 genotype in CF sibling pairs discordant for P. aeruginosa CC or NP requiring sur-
gery. We included 34 pairs and two triplets of siblings affected by CF in the study. In 23 pairs of siblings we 
observed concordance between siblings of each pair for P. aeruginosa CC and NP requiring surgery. In particular, 
in 12 sibling pairs both members were colonized and in 11 pairs of siblings both members were not colonized; 
Group PAV allele
Control subjects 103/190 (54.2%)
CF with no NP - NTH 126/252 (50.0%)
CF with NTH 33/70 (47.1%)
CF with NP requiring surgery 33/98 (33.7%)*
CF with NP requiring surgery <14 yr old 18/68 (26.4%)*
CF with no Pa CC 67/140 (47.9%)
CF with Pa CC 53/138 (38.4%)*
CF with Pa CC < 14 yr old 28/90 (31.1%)*
Table 1. Allele frequency of PAV in different subgroups of patients with CF and in control subjects. NP: nasal 
polyposis; NTH: nasal turbinate hypertrophy; Pa: Pseudomonas aeruginosa; CC: chronic colonization.. *p < 0.01 
as compared to control subjects.
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in 4 sibling pairs, both members experienced NP requiring surgery, and in 19 sibling pairs, both members did 
not experience such complications. In these 23 sibling pairs the PAV genotype was concordant (data not shown). 
As shown in Table 2, in 9 pairs and in two triplets of CF siblings we observed discordance between siblings for P. 
aeruginosa CC (5 sibling pairs) or NP requiring surgery (6 cases). In 7/11 discordant sibling pairs, both members 
Figure 1. Frequency of the PAV/PAV homozygous genotype of the TAS2R38 gene in (a) patients with CF 
and different degrees of sinonasal disease and in (b) patients with CF and P. aeruginosa chronic pulmonary 
colonization; *p < 0.01.





1A NO YES AVI/PAV
1B NO NO AVI/PAV
2A YES YES AVI/AVI
2B YES NO AVI/PAV
3A NO NO AVI/AVI
3B YES NO AVI/AVI
3C YES NO AVI/AVI
4A NO YES AVI/AAV
4B NO NO PAV/PAV
5A YES NO AAV/PAV
5B NO NO PAV/PAV
6A YES NO AVI/AVI
6B NO NO PAV/PAV
7A NO YES AVI/PAV
7B NO NO AVI/PAV
8A YES NO AVI/PAV
8B NO NO AVI/PAV
9A NO NO AVI/AVI
9B YES NO AVI/AVI
10A NO YES AVI/PAV
10B NO NO AVI/PAV
11A NO NO AVI/AVI
11B NO YES AVI/AVI
11C NO NO AVI/AVI
Table 2. Pseudomonas aeruginosa chronic colonization (CC), nasal polyposis (NP) requiring surgery and 
TAS2R38 genotype in pairs of siblings affected by CF and discordant for CC and NP.
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had the same TAS2R38 genotype. In 4/11 pairs (pairs # 2, 4, 5 and 6) we observed a different genotype and in all 
cases the PAV allele was present (homozygous or heterozygous) in the member not affected by the complication.
Discussion
Our study, performed on the largest population of patients studied so far in this field, demonstrates that the fre-
quency of the PAV allele of the TAS2R38 gene, i.e., the allele associated with the high functionality of the protein, 
was significantly reduced in CF patients with NP requiring surgery, the most advanced phase of CF sinonasal 
complications18. This finding confirms the relationship between the altered function of the TAS2R38 protein and 
the risk of upper airway infections31 and chronic rhinosinusitis28. The frequency of the PAV allele of the TAS2R38 
gene was also significantly reduced in CF patients with chronic pulmonary colonization by P. aeruginosa, suggest-
ing - for the first time - a role of the altered protein as a risk factor for lower respiratory infections.
Concerning the correlation between TAS2R38 and sinonasal diseases, in 2013, a pilot study on 28 patients 
with chronic rhinosinusitis demonstrated that supertaster patients (i.e., those with the highest activity of the 
TAS2R38 receptor being homozygous for the PAV allele) had a reduced risk of progressing to a disease requiring 
surgery. The result was later confirmed with a higher number of cases30. The same group studied 49 patients with 
CF, demonstrating that the patients homozygous for the PAV allele had a less severe sinonasal disease based 
on the SNOT score29 and the same results were reported in 123 non-CF patients with rhinosinusitis28. A single 
study that included only 53 patients with chronic rhinosinusitis and 39 healthy controls did not find associa-
tions between TAS2R38 genotypes and sinonasal disease33. Finally, a study by Cantone et al.34 on 100 subjects 
confirmed the inverse correlation between TAS2R38 functionality and the risk of developing sinonasal infec-
tions caused by gram-negative bacteria. The present study, which included 210 patients with CF and 95 control 
subjects, confirms that CF patients with both functional alleles of TAS2R38 have a significantly reduced risk of 
developing to the most severe phase of sinonasal disease, i.e., NP requiring surgery. Such complications occur 
only in 2–3% of patients with CF per year and it is still unclear why only a small subset of patients will progress 
to this phase of sinonasal disease16,18. Regarding surgical treatment, endoscopic sinus surgery for management 
of paranasal sinus diseases in CF patients is undoubtedly a challenge for the surgeon35. In the literature, surgery 
is indicated when CRS does not respond to conservative maximal medical therapy and is performed in 20–60% 
of patients with CF36. This variable frequency of surgically treated patients mirrors the absence of a consensus on 
indications and timing for surgery. In fact, no universally accepted guidelines for the surgical management of CRS 
in CF patients are available36.
Interestingly, our data relate the TAS2R38 genotype to the age of onset of NP requiring surgery, indicating that 
CF patients with nonfunctional alleles would develop NP requiring surgery at a younger age than CF patients 
with functional alleles. Thus, TAS2R38 can be considered a novel CF modifier gene, that modulates the severity of 
sinonasal disease contributing to explaining the known discordance for sinonasal severity observed in CF patients 
with the same CFTR genotype and in some pairs of CF patients4.
In addition, we also found a clear relationship between the TAS2R38 genotypes and chronic pulmonary col-
onization by P. aeruginosa. Our data indicate that CF patients with functional alleles of the gene (including some 
discordant sibling pairs) have a reduced risk of developing chronic colonization by P.aeruginosa, and have a 
decreased risk of developing colonization in childhood (i.e., before 14 years of age). There are no data so far 
with which compare our results. All the studies performed so far relate the TAS2R38 genotype only to upper 
respiratory infections, while this report is the first study that investigated patients with pulmonary colonization. 
However, considering that P. aeruginosa is among the bacteria that produce large amounts of acyl-homoserine 
lactones (known activators of the TAS2R38 receptor) we may speculate on the role of the TAS2R38 protein in 
the lower respiratory tract. Thus, if future studies confirm the present results, TAS2R38 would become a modifier 
gene that can impact P. aeruginosa infection in patients with CF. This result would help to improve management 
strategies to prevent P. aeruginosa colonization in CF patients with an elevated risk.
Materials and Methods
Study population. We recruited 210 patients with CF (105 males; age: 5–65 years; median: 20 years) fol-
lowed at the Regional Cystic Fibrosis Reference Center. All subjects gave their informed consent for inclusion 
before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, 
and the protocol was approved by the Ethics Committee of Federico II University Hospital (244–2015). All the 
subjects (guardians in the case of minors) provided written informed consent to anonymously use their DNA 
samples and clinical data for research purposes Among these subjects, we studied 34 pairs and 2 triplets of sib-
lings affected by CF. The data were anonymized. All patients met the criteria for the diagnosis of CF37. Airway 
colonization by P. aeruginosa was identified by sputum or oropharyngeal swab culture. Chronic colonization (CC) 
was defined according to the modified Leeds criteria38. The history of sinonasal disease including NTH and NP 
requiring surgery was evaluated by an otolaryngologist.
All subjects underwent the ENT (ear nose throat) examination by nasal endoscopy to assess the endoscopic 
appearance of the nose standardized by the Lund and Kennedy scale, which evaluates the clinical status of the 
nasal cavities (i.e., the presence of nasal polyps, oedema, discharge, scarring, and crusting)14. The ENT examina-
tion was performed with a 2.7-mm 30° rigid endoscope (Storz, Tuttlingen, Germany). All individuals enrolled in 
this study presented an endoscopic nasal score between 2 and 13, mean 5.65 ± 2.87, characterized by the presence 
of purulent discharge and diffuse oedema of the nasal mucosa in most of the cases. No sinonasal samplings (e.g. 
nasal lavage, nasal swabs) were performed because recent studies reported a relationship between upper and 
lower airway infection revealing concordant S. aureus and P. aeruginosa strains in upper and lower airways of the 
same patients39. No health related QoL (quality of life) assessment (e.g. SNOT-20 or SNOT-22) was performed 
because it is well known that SNOT-22 is frequently normal in patients with CF9,14.
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In addition, as control we studied, 95 healthy subjects (38 males; age: 7–66 years; median: 18 years) who pre-
sented an endoscopic nasal score of 0 and who were characterized by the absence of any endoscopic sign of CRS.
Sequencing analysis. Sweat chloride levels were tested according to the guidelines40 under quality control 
procedures41. In all patients, the CFTR genotype was defined by screening a panel of the most frequent point 
mutations42 and gene rearrangements43. Moreover, CFTR Sanger gene sequencing44 or NGS45 was performed 
when mutations were not detected in one or both alleles by first-level analysis. Furthermore, we analysed 7 intra-
genic CFTR short tandem repeats46 to verify that both members of three sibling-pairs carrying only one known 
mutation had the same CFTR genotype. DNA was extracted from blood samples with standard proteinase K 
digestion followed by phenol/chloroform extraction and ethanol precipitation. Following extraction, samples 
were quantified using a spectrophotometer (ND-1000, NanoDrop) and analysed by PCR followed by Sanger 
sequencing for TAS2R38 polymorphism assessment. We compared the frequency of the alleles and of the geno-
types in the different subgroups using the chi-square test (with Fisher correction); we considered a p value <0.01 
to be significant.
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